Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

DOI Full Paper Access

290

Citations

25

References

2007

Year

Eva Thomas, Josep Tabernero, Monica Fornier, Pierfranco Conté, P. Fumoleau, Aňa Lluch, Linda T. Vahdat, Craig A. Bunnell, Howard A. Burris, Patrice Viens,

Journal of Clinical Oncology

Abstract

Ixabepilone (40 mg/m(2) as a 3-hour infusion every 3 weeks) demonstrates promising antitumor activity and an acceptable safety profile in patients with taxane-resistant MBC.

References

	Year	Citations

Page 1